[Dilated cardiomyopathy disclosing dermatopolymyositis. Management].
Cardiac involvement in dermatopolymyositis is common but rarely symptomatic. Cardiac failure as the presentation is very rare. No correlation exists between the severity of muscular involvement and cardiac involvement. Myocarditis is not uncommon and must be borne in mind if CK MB are above 3% of total CK. It is always associated with electrocardiographic abnormalities. Corticosteroids remain first line treatment. They generally lead to regression of cardiac problems which are usually of secondary importance. If cardiac involvement is severe, the spectacular action of venoglobulins should lead to their use being envisaged from the outset, combined with corticosteroids.
Service de Médecine Interne et Immunologie Clinique, Hôpital du Bocage, Dijon.
C
C
Cuny
J C
JC
Eicher
E
E
Collet
C
C
Chatard
B
B
Chauffert
B
B
Lorcerie
F
F
Martin
J E
JE
Wolf
P
P
Louis
D002311:Cardiomyopathy, Dilated / Q000188:drug therapy / Q000209:etiology*; D003882:Dermatomyositis / Q000150:complications* / Q000628:therapy; D004359:Drug Therapy, Combination; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use*
D016756:Immunoglobulins, Intravenous; D011239:Prednisolone
Cardiomyopathie dilatée révélant une dermatopolymyosite. Attitude thérapeutique.